Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of 3 Dosages of SAP-001 in Combination With Standard of Care in Adult Subjects With Gout

NCT05690204 is registered in ClinicalTrials.gov with Shanton Pharma Pte. Ltd. as lead sponsor.

NCT NCT05690204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05690204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of 3 Dosages of SAP-001 in Combination With Standard of Care in Adult Subjects With Gout
Lead sponsor
Shanton Pharma Pte. Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 12, 2022
Completion date
February 28, 2025
Enrollment
87 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

gout